Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELONA: Elacestrant and Onapristone in ER+/PgR+/HER2- Advanced/Metastatic Breast Cancer
NCT05618613Phase 2Terminated
- Sponsor
- Context Therapeutics
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onapristone extended release and elacestrant in breast cancer, sponsored by Context Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 28 days and Objective Response Rate at 6 months. Started Dec 2022; status: terminated.
02
Drugs
onapristone extended releaseelacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05618613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618613.